News Related to PBGENE-DMD

Related coverage linked through entity extraction aliases.

FDA Grants Fast Track Designation to Precision BioSciences' DMD Gene Therapy

Mar 09, 2026

Precision BioSciences receives FDA Fast Track designation for PBGENE-DMD, a gene editing therapy for Duchenne muscular dystrophy designed to treat patients with mutations in exons 45-55.

Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD Gene Editing Therapy

Mar 09, 2026

Precision BioSciences announced FDA Fast Track designation for PBGENE-DMD, a first-in-class gene editing therapy for Duchenne muscular dystrophy targeting mutations in exons 45-55, representing up to 60% of DMD patients.